Therefore, it would be interesting to evaluate in future studies whether the hypermethylation of WNT1 could be useful for the selection of patients susceptible to systemic therapies (CDK inhibitors for example) in the BC metastatic setting. The gene discussed is WNT1; the disease is breast cancer.